Investors archive

2009 | 2008 | 2007
Movetis raises a total of €97.75m via an additional €12.75 million Over-allotment Option
21/12/2009
|
Investors
Read more >
Publication in accordance with article 14 of the Law of 2 May 2007 concerning the notification of major shareholdings (the “Transparency Law”).
15/12/2009
|
Investors
Read more >
Publication in accordance with article 15 of the Law of 2 May 2007 concerning the notification of major participations (the “Transparency Law”).
04/12/2009
|
Investors
Read more >
Movetis raises targeted €85 million in successful Initial Public Offering on Euronext Brussels
03/12/2009
|
Investors
Read more >
Movetis obtains EU authorisation for the commercialisation of Resolor® (prucalopride). First launch of Resolor anticipated in Q1 2010.
22/10/2009
|
Corporate
Read more >
Movetis receives positive opinion by the CHMP on European Marketing Authorisation Application for Resolor® (prucalopride) for the treatment of Chronic Constipation
27/07/2009
|
Scientific
Read more >
Movetis releases new data that support prucalopride’s favourable and differentiated efficacy and cardiovascular safety profile
02/06/2009
|
Scientific
Read more >
Back to overview

Print

 MailMail